Blueprint Medicines CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Blueprint Medicines Corporation has completed its acquisition by Sanofi, with shares purchased for $129.00 cash plus a contingent value right per share, leading to delisting from Nasdaq.
Blueprint Medicines Corporation announced the successful outcomes of its Annual Meeting of Stockholders held on June 18, 2025, where shareholders elected Class I directors, approved executive compensation, and ratified Ernst & Young LLP as their independent auditor.
Sanofi has announced a definitive agreement to acquire Blueprint Medicines Corporation for an upfront cash payment of $9.1 billion, plus potential contingent value rights, significantly bolstering its rare immunological disease and early-stage immunology pipeline.
Blueprint Medicines announces positive Q1 2025 financial results, highlighted by a 61% year-over-year increase in AYVAKIT net product revenues, and raises its full-year revenue guidance for AYVAKIT.
Blueprint Medicines announces positive financial results for 2024, driven by AYVAKIT sales, and provides an optimistic outlook for 2025 with significant revenue growth expected.
Blueprint Medicines provided a business and strategic update, emphasizing growth in AYVAKIT revenue, expansion of their systemic mastocytosis franchise, and the development of BLU-808 for allergic and inflammatory diseases.
Blueprint Medicines is seeking court validation of its 2024 stockholder actions due to a one-day error in setting the record date for its annual meeting.
Blueprint Medicines has increased its full-year revenue guidance for AYVAKIT after a strong third quarter, with net product revenues reaching $128.2 million.
Blueprint Medicines reported strong second-quarter results, driven by AYVAKIT sales, and raised its full-year revenue guidance.
Blueprint Medicines Corporation's stockholders approved the 2024 Stock Incentive Plan and elected three Class III directors at their annual meeting on June 12, 2024.
Blueprint Medicines has received a $150 million loan after achieving a sales milestone for its drug AYVAKIT.
Blueprint Medicines announced strong first quarter 2024 results, driven by AYVAKIT sales, and raised its full-year revenue guidance for the drug.
8-K: Blueprint Medicines Highlights Mast Cell Targeting Strategy for Allergic and Inflammatory Diseases
Blueprint Medicines Corporation presented a webinar detailing their approach to targeting mast cells for the treatment of allergic and inflammatory diseases, emphasizing their novel drug candidate BLU-808.
Blueprint Medicines has sold the U.S. rights to its cancer drug Gavreto to Rigel Pharmaceuticals for $15 million upfront, plus potential milestones and royalties, and terminated its global collaboration with Roche for the same drug.
Blueprint Medicines announced its 2023 financial results, highlighted by significant revenue growth for AYVAKIT and provided a strong revenue forecast for 2024.